Prof. Dr. Stefan Eichmüller
Phone: +49 6221 42 3380

Contact form on the DKFZ website»

Understanding immune responses against cancer...


and translating this knowledge to the clinics.

Research Group GMP & T Cell Therapy


Our group has:

  • established a GMP facility and gained a manufacturing allowance (Herstellungserlaubnis) for the production of reactivated, autologous T cells for adoptive transfer
  • identified new HLA –restricted CD4+ T cell epitopes specific for the breast cancer antigen NY-BR-1 (Int J Cancer, 2015a)
  • defined autoantibody responses against tumor antigens as prognostic factors for melanoma (Int J Cancer, 2015b) and other tumor entities
  • screened a comprehensive human miRNA library, resulting in identification of novel miRNAs inhibiting or accelerating melanoma cell invasion  and in miR-339-3p as a new tumor suppressor (Cancer Research 2016)
  • identified miR-137 and miR-101 as inhibitors of melanoma cell invasion (J Invest Dermatol, 2013; Cancer Letters 2013)

5 most significant publications

  1. Weber CEM, Luo C, Hotz-Wagenblatt A, Gardyan A, Kordaß T, Holland-Letz T, Osen W, and Eichmüller SB (in press) miR-339-3p is a tumor suppressor in melanoma. Cancer Res 76: 3562-3571.
  2. Gardyan A*, Osen W*, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, and Eichmüller SB (2015) Identification of NY-BR-1-specific CD4+ T cell epitopes using HLA-transgenic mice. Int J Cancer 136: 2588-2597.
  3. Zörnig I, Halama N, Bermejo JL, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmüller SB*, and Jäger D* (2015) Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer 136: 138-151.
  4. Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek B, Schadendorf D, Diederichs S, and Eichmüller SB (2013) miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 133: 768-775.
  5. Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D, and Eichmüller SB (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Letters 341: 240-247.


Our research is funded by the German Cancer Aid, DKTK, intramural and industrial funds.